A Study of IBI363 in Subjects With Advanced Melanoma

This study tests a new drug called IBI363 in people with advanced melanoma (skin cancer that has spread and cannot be surgically removed) whose cancer has continued growing after prior treatment. IBI363 is designed to block certain proteins that allow cancer to hide from the immune system. **You may be eligible if...** - You have been diagnosed with unresectable, locally advanced or metastatic melanoma (stage III or IV) - Your cancer has progressed after at least one prior systemic treatment - You have at least one measurable tumor - You have good overall health (ECOG 0 or 1) - Your life expectancy is at least 3 months - Women and male partners of childbearing potential agree to use effective contraception **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have active or symptomatic brain metastases - Your blood counts, liver function, or kidney function are significantly abnormal - You have a clotting disorder or recent history of blood clots - You have uncontrolled bleeding or a known bleeding tendency Talk to your doctor to see if this trial is right for you.